Jason Yongsheng Chan, Director of Research, SingHealth Duke-NUS Blood Cancer Centre and Senior Consultant Medical Oncologist at National Cancer Centre Singapore, shared a post on LinkedIn:
“It is time for reflections and projections as we conclude 2025 and welcome 2026!
The TOP FIVE highlights of the year include:
1) A personal achievement – officially ‘graduating’ from the SMU diploma in healthcare management and leadership, and reconnecting with motivated healthcare leaders from various institutions.
2) Singapore Lymphoma Scientific Symposium SLSS2025 with a sell-out 300 participants from over 14 countries and putting together papers on marginal zone lymphoma and mantle cell lymphoma from the Asian Lymphoma Study Group. Next year, the lymphoma team at NCCS will launch exciting new services and programs focusing on rare cancers and emerging novel therapeutics.
3) Obtaining significant competitive grants, particularly for Project ASPIRE supported by Tanoto Foundation. This will augment our research efforts on Asian-prevalent cancers and rare cancers starlight initiative.
4) Medical Oncology Research Day 2025 – with strong turnout from industry partners and major national agencies. The 120-member strong Department of Medical Oncology Research (DMO Research) showed up in full force in this lively event! Notably, we celebrated our collaboration with 10x Genomics, bringing the latest 10X Xenium platform to the Cancer Discovery Hub.
5) Prototype (sneakpeak!) of the DIVERSITY organoid catalogue at the STCC, as well as formation of ORION (Organoid Research and Innovative Analytics Network) at SingHealth (watch this space!).
What else do we expect in 2026? My team at the Cancer Discovery Hub will undergo a major transformation with the launch of three arms:
RESEARCH at CDH – focusing on technology integration to transform cancer science
INNOVATE at CDH – marking our entry into the innovation space for diagnostic and drug development
LEARN at CDH – for knowledge impartment to young investigators and talent development
These arms represent our commitment to drive our cancer research translation capabilities to the next frontier, especially on single cell and spatial technologies (10x Genomics, BGI · Research STOmics, Singleron Biotechnologies NanoString Technologies, Inc.), long read sequencing (Oxford Nanopore Technologies) and novel NGS platforms (Twist Bioscience Agilent Technologies Illumina PacBio Dovetail Genomics).
Looking forward to 2026 with everyone. Wishing all a Happy New Year ahead!”
More posts featuring Jason Yongsheng Chan.
